CinCor Pharma Inc (CINC)

29.06 0.00 (0.00%)
Close USD Disclaimer

CinCor Pharma Inc Company Profile

Industry
-
Sector
-
Employees
19
Equity Type
ORD
CinCor Pharma, Inc., a clinical-stage biopharmaceutical company, engages in the development of drugs for the treatment for cardio-renal diseases. It is involved in developing CIN-107, which is in Phase II clinical trial for the treatment of hypertension, primary aldosteronism, and other cardio-renal diseases, as well as in Phase I clinical trial to treat chronic kidney diseases. The company was incorporated in 2018 and is based in Waltham, Massachusetts. As of February 23, 2023, CinCor Pharma, Inc. operates as a subsidiary of AstraZeneca Finance and Holdings Inc.
Contact Information
Address
Waltham,02451 United States
Phone
513-800-2585
Fax
-

Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.

Related Articles